Manipulating the Primary Cilia Promises Treatments for OA
Hairy treatment for osteoarthritis… next
Manipulating the Primary Cilia Promises New Treatments for Osteoarthritis
Reported in Doctor Pulse, this item…In a study published in the journal FASEB, scientists show that medical manipulation of the primary cilia, tiny hair-like structures protruding from the surface of most human cells, disrupts a key biological process called ‘Hedgehog Signalling’. The study reveals lithium chloride, a drug often used to treat bipolar disorder, can enlarge the size of primary cilia in several cell types.
The study is the first to use a new state of the art super resolution imaging technique – structural illumination microscopy (SIM) to observe detailed images of how the drug affects the structure of primary cilia. They exposed human and bovine cartilage cells to varying doses of lithium chloride over a 24 hour period and recorded the length of the primary cilia and the activation of Hedgehog Signalling.
“Scientists are beginning to realize that primary cilia, which were once thought to be irrelevant are actually involved in a number of key biological processes,” Co-author Professor Martin Knight from Queen Mary’s School of Engineering and Materials Science and the Institute of Bioengineering, explains. “Previous studies from our group demonstrate how the length of primary cilia play a role in stem cell differentiation, and this current study provides further insight.”
Comment: Hairy indeed.
Samumed, LLC Announces Successful Modulation Of The Wnt Pathway For Potential Cartilage Regeneration
At the American College of Rheumatology (ACR) Annual Meeting, Samumed unveiled groundbreaking pre-clinical and clinical research that demonstrated successful modulation of the Wnt pathway for potential applications in regenerative medicine. Samumed researchers have developed an injectable investigational drug that inhibits the Wnt pathway, causing a person’s own stem cells to regenerate knee cartilage in animals. Clinical data indicate that the same investigational drug may slow joint space narrowing and possibly increase joint space in the knee. Clinicians generally perceive an increase in joint space as evidence of preservation or regrowth of cartilage.
“The results of our Phase I study of SM04690 for the treatment of osteoarthritis of the knee are very encouraging,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “We believe that the clinical trial results we have seen to date, combined with the success of our animal results, demonstrate that our technology could potentially be the basis of a safe and effective treatment for the millions of patients suffering from osteoarthritis of the knee.”
Comment: definitely worth following here.
What’s the best drug for delaying knee replacement… next
Study finds best anti-inflammatory for delaying knee osteoarthritis’ progression
Michael Johnsen writing for Drug Store News reported chondroitin sulfate is superior to an anti-inflammatory drug, celecoxib, for delaying the progression of knee osteoarthritis, according to a new study presented by Jean-Pierre Pelletier, from the University of Montreal (Canada), at the official press conference of the Annual meeting of the American College of Rheumatology.
The study, named MOSAIC, was a multicenter, randomized, double blind, controlled and comparative study analyzing chondroitin sulfate and celecoxib. The study recruited 194 patients suffering from knee osteoarthritis with inflammation and moderate pain. Participants were divided into two groups: the first group received 1,200 mg of pharmaceutical grade chondroitin sulfate (made by Bioiberica) per day, while the second group received 200 mg of celecoxib per day, over a two-year period. The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, a second one after one year, and a third one at the end of the study.
The results revealed that the progression of knee osteoarthritis is slower in patients receiving chondroitin sulfate. More precisely, this group experienced a statistically significant lower loss of cartilage volume after the first year of treatment, in comparison with those patients who received the anti inflammatory drug. “This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and that it had a disease-modifying effect,” affirmed Pelletier.
The study also evaluated the effects of both drugs on pain, function, stiffness, joint efflux and swelling; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50%.
“The study confirmed that both drugs are efficient for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect and a better safety profile,” Pelletier said.
Comment: a neutriceutical that outperforms a pharmaceutical. Wow!!
A very promising method for regenerating cartilage…
A brand new treatment for osteoarthritis… next
New treatment could ease the agony of arthritis: Tiny bubbles made by the body’s own cells may slash the need for surgery
Fiona Macrae writing for the Daily Mail reported a bubble-based treatment that could ease the pain of arthritis and cut the need for hip replacements is being developed by British scientists.
It uses tiny particles that are naturally made by the body to protect and repair damaged joints.
This should mean that arthritis is better treated – reducing pain and improving movement of millions.
It may also cut the need for painful, complicated and expensive hip and knee replacement operations.
Scientists have discovered tiny bubbles called microvesicles, made by the body’s own cells, may ‘cure’ the cartilage of arthritis sufferers
The hope centres on microvessicles – tiny, fluid-filled bubbles made by the body’s cells.
Research at Queen Mary University of London has shown that the thick fluid that bathes the joints in arthritis sufferers is rich microvessicles that are battling against the disease.
These microvessicles are packed with a protein called Annexin A1 that protects the cartilage that lines and cushions the joints from arthritis.
In experiments on arthritic mice, an injection of the microvessicles into the joints reduced cartilage damage. Plus, arthritis was worse in mice that made lower than usual levels of these microvessicles.
The protein may even repair damage.
Comment: Exciting news indeed.
Good news for RA patients… next
Heart disease-related deaths among US rheumatoid arthritis patients declined
Evan Douglas writing in wwntradio reported heart disease-related deaths among US rheumatoid arthritis patients declined.
Rheumatoid arthritis patients are twice as likely as the average person to develop heart disease, but a new study shows that efforts to prevent heart problems and diagnose and treat heart disease early may be paying off. Despite the heightened danger, deaths from cardiovascular disease among people with rheumatoid arthritis are declining, the research found. The study by the Mayo clinic was presented at the American College of Rheumatology’s annual meeting.
Dr. Elena Myasoedova, lead author of the study, believes that further research should be done to confirm why cardiac deaths among patients with rheumatoid arthritis have dropped, but factors such as improved treatment for rheumatoid and cardiovascular diseases, early screening for heart problems and more attention to the heart health of patients have indeed influenced the drop.
Comment: this is really good news since it means our therapies are working not only on the joints but on the rest of the organ systems as well.